Please ensure Javascript is enabled for purposes of website accessibility

Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma

By Eric Volkman – Oct 2, 2020 at 7:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's not the first time Opdivo and Yervoy have gotten the nod to treat a form of cancer.

Bristol Myers Squibb (BMY 1.58%) capped the week with a new approval from the Food and Drug Administration (FDA). On Friday, the regulator gave the green light for two of the pharmaceutical giant's drugs, Opdivo and Yervoy, to be used in combination to treat a form of mesothelioma. This is a form of cancer that affects the mesothelium, the thin layer of tissue covering many of the body's internal organs.

Specifically, Opdivo and Yervoy can be used in the first-line treatments of adult patients with malignant pleural mesothelioma (MPM) -- a disease of the mesothelium lining the lungs -- that cannot be removed surgically. It can result from the absorption of asbestos fibers, and according to the FDA roughly 20,000 people in the U.S. are diagnosed with it annually.

Cancer attacking an organism.

Image source: Getty Images.

Both Opdivo and Yervoy have previously been approved by the FDA as monotherapies to treat different types of cancer. In combination, they are approved for use to combat previously untreated kidney cancer.

This marks the second approval of a combination therapy for MPM; in 2004 it gave the nod to a pair of other oncological drugs, pemetrexed and cisplatin. 

The FDA quoted its director of the Office of Oncologic Diseases Richard Pazdur as saying that "now patients... have an important, additional treatment option after more than a decade with only one FDA-approved drug regime."

In a press release on Friday, the company quoted its head of oncology development Sabine Maier, who said that it "remain[s] committed to continued research in melanoma, both to further understand the potential benefit of Yervoy in combination with Opdivo to treat high-risk melanoma patients in the earlier stages of disease, as well as to study additional novel combinations in various settings."

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol-Myers Squibb Stock Quote
Bristol-Myers Squibb
BMY
$80.28 (1.58%) $1.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.